EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression through disrupted ribosome biogenesis

Chiao-Yun Lin, An-Shine Chao, Angel Chao, Ren-Chin Wu, Alice L Yu, Chiung-Hui Fu, Yu-Chuan Teng, Ruby Yun-Ju Huang, Chyong-Huey Lai

Journal of Molecular Medicine · 2026-12 · 104 (1)

DOI: 10.1007/s00109-026-02638-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Medicine, online erschienen am 24.01.2026. Verfasst von Chiao-Yun Lin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Gynecologic Cancer Research Center, Linkou Branch, Chang Gung Memorial Hospital, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Ribosomes, Receptor Protein-Tyrosine Kinases, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Science and Technology Council, Chang Gung Memorial Hospital, Linkou, Yushan Young Fellow Program from Ministry of Education..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OCCC has extremely poor prognosis. ARID1A mutation-related chromatin remodeling errors are key molecular features of OCCC. Dysregulation of receptor tyrosine kinases-related signaling pathways is common in OCCC. Here we show that combination of niraparib and lenvatinib exhibits significant synergistic inhibitory effects against platinum-resistant OCCC cell lines, xenografts, patient-derived tumoroid (PDT) models, and prolonged survival in the platinum-refractory patient-derived xenograft (PDX) model. RNA-sequencing revealed the most differently expressed genes in PDX treated with a combination of niraparib and lenvatinib versus control were in structural ribosomal components. Selected differently expressed ribosomal proteins (RPs: RPS2, RPS5, RPS9, and RPL3) was validated using quantitative polymerase chain reaction. Nucleophosmin (NPM1) expression, which is involved in ribosome biogenesis, was inhibited by niraparib and lenvatinib. Our findings imply that combined niraparib and lenvatinib reduces platinum-resistant OCCC progression by attenuating Src phosphorylation, NPM1 expression and ribosome biogenesis. These results highlight the necessity for continued exploration of this promising treatment strategy, particularly in future clinical trials for platinum-resistant or platinum-refractory OCCC. KEY MESSAGES: The combination of niraparib and lenvatinib synergistically inhibits platinum-resistant OCCC. This combination prolongs survival in a platinum-refractory PDX model. RNA sequencing revealed that the most differentially expressed genes in PDX models treated with this combination were associated with structural ribosomal components. This combination suppresses Src phosphorylation, NPM1 expression, and ribosomal protein levels in OCCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsRibosomesReceptor Protein-Tyrosine KinasesPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesFemaleHumansNucleophosminAnimalsCell Line, TumorMiceXenograft Model Antitumor AssaysNuclear ProteinsIndazolesPhenylurea CompoundsGene Expression Regulation, NeoplasticDisease Progression

Stichwörter der Autor:innen

LenvatinibNirapaibNucleophosmin (NPM1)Ovarian clear cell carcinomaPatient-derived tumoroid (PDT)Patient-derived xenograft (PDX)

Substanzen

NucleophosminNPM1 protein, humanReceptor Protein-Tyrosine KinasesPoly(ADP-ribose) Polymerase InhibitorsNuclear ProteinsIndazolesPoly(ADP-ribose) PolymerasesNpm1 protein, mousePhenylurea Compounds

Autor:innen und Institutionen

  • Gynecologic Cancer Research Center, Linkou Branch, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
  • Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Linkou Branch, Chang Gung University College of Medicine, 5 Fu-Shin St, Guishan, Taoyuan, 333, Taiwan.
  • Department of Obstetrics and Gynecology, New Taipei Municipal Tu Cheng Hospital, New Taipei City, Taiwan.
  • Department of Pathology, Chang Gung Memorial Hospital Linkou Medical Center, Chang Gung University College of Medicine, Taoyuan, Taiwan.
  • Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Linkou Branch, Chang Gung University, Taoyuan, Taiwan.
  • Taiwan Advanced Nanotech Inc, Taoyuan, Taiwan.

Förderung

  • National Science and Technology Council
  • Chang Gung Memorial Hospital, Linkou
  • Yushan Young Fellow Program from Ministry of Education.

Zitieren

APA

Lin, C. Y., Chao, A. S., Chao, A., Wu, R. C., Yu, A. L., Fu, C. H., Teng, Y. C., Huang, R. Y., & Lai, C. H. (2026). Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression through disrupted ribosome biogenesis. Journal of Molecular Medicine, 104(1). https://doi.org/10.1007/s00109-026-02638-0

Vancouver

Lin CY, Chao AS, Chao A, Wu RC, Yu AL, Fu CH, et al. Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression through disrupted ribosome biogenesis. Journal of Molecular Medicine. 2026;104(1). doi:10.1007/s00109-026-02638-0

BibTeX
@article{Lin2026,
  author = {Lin, Chiao-Yun and Chao, An-Shine and Chao, Angel and Wu, Ren-Chin and Yu, Alice L and Fu, Chiung-Hui and Teng, Yu-Chuan and Huang, Ruby Yun-Ju and Lai, Chyong-Huey},
  title = {Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression through disrupted ribosome biogenesis},
  journal = {Journal of Molecular Medicine},
  year = {2026},
  volume = {104},
  number = {1},
  doi = {10.1007/s00109-026-02638-0}
}
Kostenlos starten →